In particular, study of tumor biopsies has made possible to highlight the importance of tumor-infiltrating leucocytes (TIL) i.e., effector CD8+ T cells and TLS-B cells with regard to the clinical outcome (3, 4) and response to anti-immune checkpoint therapies (5–7). The gene discussed is CD8A; the disease is neoplasm.